Welcome to our dedicated page for Phathom Pharmaceuticals news (Ticker: PHAT), a resource for investors and traders seeking the latest updates and insights on Phathom Pharmaceuticals stock.
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, and its news flow reflects this GI specialization. Company updates frequently center on VOQUEZNA (vonoprazan), a first-in-class potassium-competitive acid blocker (PCAB) that Phathom markets in the United States for adult patients with Erosive GERD, Non-Erosive GERD, and Helicobacter pylori infection in combination regimens.
Investors and healthcare observers following PHAT news can expect regular announcements on commercial performance, including prescription milestones and revenue updates tied to VOQUEZNA tablets, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Phathom’s press releases have highlighted metrics such as total VOQUEZNA prescriptions dispensed in the United States and quarterly financial results, often accompanied by commentary on commercialization strategy and expense trends.
Another major category of Phathom news involves clinical and scientific developments. The company reports progress in trials like the Phase 3 pHalcon-NERD-301 study in Non-Erosive GERD and the Phase 2 pHalcon-EoE-201 study evaluating VOQUEZNA in eosinophilic esophagitis. Publications in peer-reviewed journals and presentations at gastroenterology conferences, such as the American College of Gastroenterology Annual Scientific Meeting, are common topics in its releases.
Phathom also issues news on capital markets activity, including proposed and priced underwritten public offerings of common stock and pre-funded warrants, as well as corporate updates such as leadership appointments and participation in investor conferences. Together, these news items provide a view into the company’s GI-focused strategy, clinical pipeline, commercial trajectory, and financing plans. For users tracking PHAT, the news page offers a consolidated stream of these developments over time.
Phathom Pharmaceuticals (Nasdaq: PHAT) announces that CVS Caremark, the largest pharmacy benefit manager in the U.S., has added VOQUEZNA® (vonoprazan) tablets to its national formularies for over 26 million commercially insured members. This addition brings the estimated total of commercially covered lives with access to VOQUEZNA to over 116 million.
VOQUEZNA is the first major innovation in Gastroesophageal Reflux Disease (GERD) treatment in over 30 years and the only FDA-approved potassium-competitive acid blocker (PCAB) available in the U.S. It is approved for the relief of heartburn associated with Non-Erosive GERD and for the treatment of all severities of Erosive Esophagitis.
Phathom's Chief Commercial Officer, Martin Gilligan, stated that an estimated 77% of total commercial lives now have access to VOQUEZNA. The company is offering savings programs for eligible patients, including a savings card program allowing eligible commercially insured patients to pay as little as $25 for their prescription.
Phathom Pharmaceuticals (Nasdaq: PHAT), a biopharmaceutical company focused on gastrointestinal diseases, has announced it will host a live webcast on Thursday, August 8, 2024, at 8:30 am ET to report its second quarter 2024 financial results and provide a business update. The webcast will be accessible on the company's website and will be available for 90 days following the event.
Phathom specializes in developing and commercializing novel treatments for gastrointestinal diseases. The company has exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) marketed in the US as VOQUEZNA® for various GERD-related treatments and VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® for H. pylori infection treatment in adults.
Phathom Pharmaceuticals announces FDA approval of VOQUEZNA® (vonoprazan) 10 mg tablets for the relief of heartburn associated with Non-Erosive Gastroesophageal Reflux Disease (GERD) in adults. This marks VOQUEZNA's third FDA approval, following treatments for Erosive Esophagitis and H. pylori infection.
VOQUEZNA represents the first major innovation in GERD treatment in over 30 years, targeting the largest category of GERD affecting an estimated 45 million U.S. adults. In the Phase 3 PHALCON-NERD-301 study, VOQUEZNA demonstrated significant and rapid reduction of heartburn, with 45% heartburn-free days compared to 28% for placebo.
The approval provides a novel treatment option for millions of Non-Erosive GERD patients who remain dissatisfied with current therapies. VOQUEZNA is now available via prescription, with savings programs offered for eligible patients facing coverage or affordability issues.
Phathom Pharmaceuticals (Nasdaq: PHAT) will participate in two key investor conferences in June 2024. The company will present at the Jefferies Global Healthcare Conference in New York on June 5 at 12:30 p.m. ET, and at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach on June 11 at 2:40 p.m. ET. Both events will feature live webcasts and archived recordings available on Phathom's website for 90 days post-conference. Management will also hold one-on-one meetings throughout both conferences.
Phathom Pharmaceuticals will present data on VOQUEZNA® (vonoprazan) at Digestive Disease Week® (DDW) 2024, held from May 18-21 in Washington, D.C. The company will showcase Phase 3 results for Non-Erosive Reflux Disease (NERD) and research on Erosive GERD, shedding light on health care resource utilization and treatment patterns. The U.S. FDA has accepted Phathom's New Drug Application for VOQUEZNA as a daily treatment for heartburn associated with Non-Erosive GERD, with a target action date of July 19, 2024.
Phathom Pharmaceuticals reported net revenues of $1.9 million for the first full quarter of launch, with over 17,500 prescriptions dispensed, representing a 361% increase. Cigna Healthcare added VOQUEZNA tablets to its formularies, broadening coverage to approximately 48% of all U.S. commercial lives. The company is hosting a conference call to discuss the positive progress of VOQUEZNA in treating Erosive GERD. A direct-to-consumer campaign is actively increasing brand awareness, with future clinical trials and expanded indications on the horizon.
Phathom Pharmaceuticals, Inc. will report its first quarter 2024 financial results and provide a business update on Thursday, May 9, 2024. The company, listed on Nasdaq as PHAT, focuses on developing and commercializing novel treatments for gastrointestinal diseases. A live webcast will be hosted at 8:30 am ET on the mentioned date, with access to the presentation available on the company's website.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Phathom Pharmaceuticals (PHAT)?
What is the market cap of Phathom Pharmaceuticals (PHAT)?
